Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Among authors: macpherson e. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J. Samol J, et al. Among authors: macpherson e. Invest New Drugs. 2012 Aug;30(4):1493-500. doi: 10.1007/s10637-011-9682-9. Epub 2011 May 18. Invest New Drugs. 2012. PMID: 21590367 Clinical Trial.
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Ledermann J, et al. Among authors: macpherson e. N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27. N Engl J Med. 2012. PMID: 22452356 Free article. Clinical Trial.
Predicting mortality in febrile adults: comparative performance of the MEWS, qSOFA, and UVA scores using prospectively collected data among patients in four health-care sites in sub-Saharan Africa and South-Eastern Asia.
Lal S, Luangraj M, Keddie SH, Ashley EA, Baerenbold O, Bassat Q, Bradley J, Crump JA, Feasey NA, Green EW, Kain KC, Olaru ID, Lalloo DG, Roberts CH, Mabey DCW, Moore CC, Hopkins H; Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE) Study Consortium. Lal S, et al. EClinicalMedicine. 2024 Oct 4;77:102856. doi: 10.1016/j.eclinm.2024.102856. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39416389 Free PMC article.
Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing.
DeRidder LB, Hare KA, Lopes A, Jenkins J, Fitzgerald N, MacPherson E, Fabian N, Morimoto J, Chu JN, Kirtane AR, Madani W, Ishida K, Kuosmanen JLP, Zecharias N, Colangelo CM, Huang HW, Chilekwa M, Lal NB, Srinivasan SS, Hayward AM, Wolpin BM, Trumper D, Quast T, Rubinson DA, Langer R, Traverso G. DeRidder LB, et al. Among authors: macpherson e. Med. 2024 Jul 12;5(7):780-796.e10. doi: 10.1016/j.medj.2024.03.020. Epub 2024 Apr 24. Med. 2024. PMID: 38663403
152 results